iBio to Present Preclinical Data on First-in-Class Activin E Antibody IBIO-610 for Obesity Treatment
Key Insights
iBio will present new preclinical data on its Activin E (search) antibody IBIO-610 (search) at ObesityWeek 2025 and PEGS Europe 2025, showcasing results from non-human primate studies.
The company's research suggests that inhibiting Activin E (search) signaling could deliver fat-selective weight loss and support long-term weight maintenance while enhancing GLP-1 therapy benefits.
IBIO-610 (search) represents a first-in-class approach that may overcome key limitations of current obesity therapies and advance next-generation cardiometabolic treatments.
iBio, Inc. (NASDAQ:IBIO) announced it will present new preclinical data on its first-in-class Activin E (search) antibody, IBIO-610 (search), at two major scientific conferences this November. The AI-driven precision antibody therapy company will showcase findings from non-human primate studies that support the therapeutic potential of targeting Activin E signaling for obesity treatment.
Dr. Martin Brenner, Chief Executive Officer and Chief Scientific Officer of iBio, emphasized the significance of the research findings. "We are excited to share additional data from the non-human primates study of our Activin E (search) antibody, IBIO-610 (search), which continues to support its potential as a differentiated approach to the treatment of obesity," said Dr. Brenner.
Novel Mechanism Shows Promise for Cardiometabolic Disorders
The preclinical data suggests that inhibiting Activin E (search) signaling could deliver fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies. According to Dr. Brenner, "These findings add to a growing body of research that inhibiting Activin E signaling could deliver fat-selective weight loss, support long-term weight maintenance, and enhance the benefits of GLP-1 therapies."
The research indicates that IBIO-610 (search) could help overcome key limitations of current therapies and advance the next generation of cardiometabolic treatments. This represents a potentially significant advancement in obesity therapeutics, as current treatments often face challenges with long-term efficacy and weight maintenance.
Conference Presentations Detail Research Progress
At ObesityWeek 2025 in Atlanta, Dr. Cory Schwartz, Director of Research and Early Development at iBio, will deliver an oral presentation titled "Discovery and Testing of a First-in-Class Activin E (search) Antagonist Antibody for the Treatment of Obesity" on November 4, 2025, from 2:00 p.m. to 2:15 p.m. EST. Dr. Schwartz will also present a poster on November 5 titled "Preclinical Evaluation of a Long-Acting Anti-Myostatin Therapy for Obesity."
At PEGS Europe 2025 in Lisbon, Dr. Brenner will present "A First-in-Class Anti-Activin E (search) Antibody Induces Fat-Selective Weight-Loss in Diet-Induced Obese Mice" on November 12, 2025, from 11:45 a.m. to 12:15 p.m. WET as a podium presentation.
Advancing Precision Medicine for Metabolic Disorders
iBio combines proprietary 3D modeling with innovative drug discovery platforms to develop breakthrough antibody treatments for cardiometabolic diseases, obesity, cancer, and other hard-to-treat diseases. The company's approach leverages AI and advanced computational biology to accelerate development timelines and create next-generation biopharmaceuticals.
The upcoming presentations will provide the scientific community with detailed insights into IBIO-610 (search)'s mechanism of action and its potential to address significant unmet medical needs in obesity treatment. The data from both mouse models and non-human primate studies will offer a comprehensive view of the antibody's therapeutic potential and safety profile.